InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer.
11 affiliations
- 1Department of Radiation Oncology, University of Bonn, University Hospital Bonn, Bonn, Germany.
- 2Department of Hematology, Oncology & Stem Cell Transplantation, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- 3Institute of Experimental Oncology, University of Bonn, University Hospital Bonn, Bonn, Germany.
- 4AstraZeneca GmbH, Hamburg, Germany.
- 5Medical Clinic III of Oncology, Hematology, Rheumatology, and Immune Oncology, University of Bonn, University Hospital Bonn, Bonn, Germany.
- 6Praxis-Netzwerk Onkologie, Troisdorf, Germany.
- 7Department of Radiation Oncology, Klinikum Stuttgart, Stuttgart, Germany.
- 8Department of Radiation Oncology, University of Leipzig, University Hospital Leipzig, Leipzig, Germany.
- 9Department of Radiation Oncology, University of Freiburg, University Medical Center Freiburg, Freiburg, Germany.
- 10Department of Thoracic Surgery, University of Bonn, University Hospital Bonn, Bonn, Germany.
- 11Department of Thoracic Surgery, University of Freiburg, University Medical Center Freiburg, Freiburg, Germany.
Abstract
Background
The optimal integration of surgery and definitive chemoradiotherapy (CRT) following modern neoadjuvant immunochemotherapy in stage IIB-IIIA/B non-small-cell lung cancer (NSCLC) remains controversial. Although immune checkpoint inhibitors have substantially improved outcomes in both resectable and unresectable disease, prospective randomized data directly comparing surgery and definitive CRT after neoadjuvant immunochemotherapy are lacking.Methods
InDuRanS is a prospective, multicenter, randomized, open-label phase II trial conducted in Germany. Patients with (borderline) resectable stage IIB-IIIA/B (N2) NSCLC receive three cycles of neoadjuvant immunochemotherapy with durvalumab plus platinum-paclitaxel. Patients with persistent resectability are randomized 1:1 to surgery or definitive CRT. Both treatment arms receive consolidation durvalumab for up to 12 months. The primary endpoint is 2-year event-free survival in 158 randomized patients. Key secondary endpoints include progression-free survival, overall survival, safety and tolerability, health-related quality of life, and an extensive exploratory translational research program.Discussion
InDuRanS is the first randomized trial to directly compare surgery versus definitive CRT within a contemporary multimodal treatment sequence incorporating both neoadjuvant and consolidation immunotherapy in stage IIB-IIIA/B NSCLC. Its results are expected to help define optimal local treatment strategies in an evolving therapeutic landscape. InDuRanS is currently active and open to enrollment as of April 2025, with primary completion anticipated in 2028 (NCT06810609).
Related
- Efficacy and safety analysis of consolidation immunotherapy following definitive concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
- Definitive radiotherapy versus surgery after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma: a propensity score-matched study of efficacy and safety
- Prognostic impact of immune-related adverse events in non-completers of durvalumab consolidation therapy for non-small cell lung cancer: a single-center retrospective cohort study
- Neutrophil-epithelial niches arrest B-cell maturation in dysfunctional tertiary lymphoid structures of gastric cancer neoadjuvant immunochemotherapy.
- Paraneoplastic Neurological Syndrome in a Patient with Limited-stage Small-cell Lung Cancer Receiving Durvalumab Maintenance after Concurrent Chemoradiotherapy: A Case Report
BibTeX
@article{gkika2026indurans,
title = {{InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer.}},
author = {Eleni Gkika and Cornelius F Waller and Cas S Dejonckheere and Julian P Layer and Jan Meiners and Peter Brossart and Ernst Rodermann and Anne Sofie Schiefer and Marc Münter and Nils H Nicolay and Anca L Grosu and Andreas Rimner and Joachim Schmidt and Severin Schmid},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1909979},
url = {https://europepmc.org/article/MED/42908627},
note = {CC BY},
}
RIS
TY - JOUR
TI - InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer.
AU - Eleni Gkika
AU - Cornelius F Waller
AU - Cas S Dejonckheere
AU - Julian P Layer
AU - Jan Meiners
AU - Peter Brossart
AU - Ernst Rodermann
AU - Anne Sofie Schiefer
AU - Marc Münter
AU - Nils H Nicolay
AU - Anca L Grosu
AU - Andreas Rimner
AU - Joachim Schmidt
AU - Severin Schmid
PY - 2026
DA - 2026/10/07
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1909979
UR - https://europepmc.org/article/MED/42908627
AB - Background The optimal integration of surgery and definitive chemoradiotherapy (CRT) following modern neoadjuvant immunochemotherapy in stage IIB-IIIA/B non-small-cell lung cancer (NSCLC) remains controversial. Although immune checkpoint inhibitors have substantially improved outcomes in both resectable and unresectable disease, prospective randomized data directly comparing surgery and definitive CRT after neoadjuvant immunochemotherapy are lacking.Methods InDuRanS is a prospective, multicenter, randomized, open-label phase II trial conducted in Germany. Patients with (borderline) resectable stage IIB-IIIA/B (N2) NSCLC receive three cycles of neoadjuvant immunochemotherapy with durvalumab plus platinum-paclitaxel. Patients with persistent resectability are randomized 1:1 to surgery or definitive CRT. Both treatment arms receive consolidation durvalumab for up to 12 months. The primary endpoint is 2-year event-free survival in 158 randomized patients. Key secondary endpoints include progression-free survival, overall survival, safety and tolerability, health-related quality of life, and an extensive exploratory translational research program.Discussion InDuRanS is the first randomized trial to directly compare surgery versus definitive CRT within a contemporary multimodal treatment sequence incorporating both neoadjuvant and consolidation immunotherapy in stage IIB-IIIA/B NSCLC. Its results are expected to help define optimal local treatment strategies in an evolving therapeutic landscape. InDuRanS is currently active and open to enrollment as of April 2025, with primary completion anticipated in 2028 (NCT06810609).
SN - 2234-943X
ER -